Table 1.
Characteristic | Definite or Probable TBM | Not TBM | P | FujiLAM Positive | FujiLAM Negative | P |
---|---|---|---|---|---|---|
Age, years | 33 (26–40) | 37 (29–48) | .04 | 32 (26–40) | 37 (28–45) | .04 |
Women, n (%) | 21 (36) | 16 (37) | .9 | 12 (39) | 25 (36) | .8 |
MRC grade, n (%) | .02 | .01 | ||||
1 | 10 (17) | 15 (44) | 3 (10) | 22 (36) | ||
2 | 35 (60) | 16 (47) | 20 (65) | 31 (51) | ||
3 | 13 (22) | 3 (9) | 8 (26) | 8 (13) | ||
GCS <15 | 46 (79) | 23 (55) | .02 | 28 (90) | 41 (59) | .002 |
Headache symptom | 51 (86) | 32 (76) | .3 | 27 (87) | 55 (80) | .6 |
Illness duration, days | 30 (14–30) | 21 (14–60) | .39 | 30 (14–60) | 24.5 (14–30) | .23 |
CD4 T cells/µL | 79 (30–260) | 102 (45–232) | .48 | 46 (18–86) | 153 (45–273) | .04 |
<100 CD4 cells/µL, n (%) | 13 (57) | 4 (44) | .7 | 9 (82) | 8 (38) | .03 |
Pulmonary or extrapulmonary TB, n (%) | 27 (47) | 7 (16) | .002 | 15 (48) | 19 (27) | .04 |
CSF WBC, cells/µL | 65 (<5–245) | <5 (<5–35) | .003 | 87.5 (<5–240) | <5 (<5–80) | .03 |
CSF protein, mg/dL | 116 (72–184) | 74 (36–118) | .02 | 119 (72–187) | 99 (53–134) | .2 |
CSF glucose, mg/dL | 29 (19–68) | 82 (65–107) | <.001 | 22 (18–54) | 75 (36–100) | .005 |
CSF lactate, mmol/L | 7.5 (3.9–9.5) | 2.3 (2.0–3.1) | <.001 | 9.5 (4.3–10) | 2.9 (2–7.2) | .002 |
14-Day mortality, n (%) | 17 (29) | 9 (21) | .5 | 10 (32) | 16 (23) | .3 |
Data are presented as n (%) or medians with interquartile range. CD4 T-cell count was only available for the latter portion of the cohort (n = 32). Pulmonary or extrapulmonary TB is based upon detection by Xpert Ultra or AlereLAM in sputum or urine, or suggestive chest radiography or abdominal ultrasound. Abbreviations: CSF, cerebrospinal fluid; FujiLAM, Fujifilm SILVAMP TB LAM; GCS, Glasgow Coma Scale; MRC, British Medical Research Council grade for TBM (this grade was available for n = 92 participants); TB, tuberculosis; TBM, tuberculous meningitis; WBC, white blood cell count.